Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Denali Therapeutics (DNLI) Non Operating Income: 2016-2023

Historic Non Operating Income for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2023 value amounting to $51.5 million.

  • Denali Therapeutics' Non Operating Income rose 97.13% to $13.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $51.5 million, marking a year-over-year increase of 248.62%. This contributed to the annual value of $51.5 million for FY2023, which is 248.62% up from last year.
  • Per Denali Therapeutics' latest filing, its Non Operating Income stood at $51.5 million for FY2023, which was up 248.62% from $14.8 million recorded in FY2022.
  • Denali Therapeutics' 5-year Non Operating Income high stood at $51.5 million for FY2023, and its period low was $4.6 million during FY2021.
  • For the 3-year period, Denali Therapeutics' Non Operating Income averaged around $23.6 million, with its median value being $14.8 million (2022).
  • Its Non Operating Income has fluctuated over the past 5 years, first crashed by 50.28% in 2021, then spiked by 248.62% in 2023.
  • Yearly analysis of 5 years shows Denali Therapeutics' Non Operating Income stood at $15.2 million in 2019, then plummeted by 39.28% to $9.2 million in 2020, then plummeted by 50.28% to $4.6 million in 2021, then soared by 221.52% to $14.8 million in 2022, then skyrocketed by 248.62% to $51.5 million in 2023.